(HALO) Halozyme Therapeutics - Ratings and Ratios
Hyaluronidase Enzyme, Hylenex, Hyqvia, XYOSTED
HALO EPS (Earnings per Share)
HALO Revenue
Description: HALO Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes proprietary enzymes and devices. Their patented recombinant human hyaluronidase enzyme (rHuPH20) is the foundation for their products, enabling the delivery of injectable biologics, small molecules, and fluids. The companys product portfolio includes Hylenex recombinant, XYOSTED, and ATRS-1902, among others.
The companys products are used in various therapeutic areas, including oncology, autoimmune diseases, and hormonal therapies. They have partnered with several major pharmaceutical companies, including F. Hoffmann-La Roche, Takeda Pharmaceuticals, Pfizer, and AbbVie, to develop and commercialize their products. Some of the notable partnered products include Herceptin, Mabthera SC, and DARZALEX.
From a financial perspective, Halozyme Therapeutics has a market capitalization of approximately $6.97 billion, with a price-to-earnings ratio of 15.05 and a forward P/E of 12.14. The companys return on equity is 122.24%, indicating a strong financial performance. To further evaluate the companys performance, we can look at key performance indicators (KPIs) such as revenue growth, research and development (R&D) expenses, and operating margin. A review of these KPIs can provide insights into the companys ability to drive growth, invest in R&D, and maintain profitability.
Some additional KPIs to consider when evaluating Halozyme Therapeutics include their cash and cash equivalents, total debt, and cash flow from operations. These metrics can provide insights into the companys financial health, ability to meet its financial obligations, and capacity to invest in new projects and initiatives. By analyzing these KPIs, investors and analysts can gain a more comprehensive understanding of Halozyme Therapeutics financial performance and potential for future growth.
HALO Stock Overview
| Market Cap in USD | 9,068m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2004-03-16 |
HALO Stock Ratings
| Growth Rating | 62.7% |
| Fundamental | 85.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 3.04% |
| Analyst Rating | 3.63 of 5 |
HALO Dividends
Currently no dividends paidHALO Growth Ratios
| Growth Correlation 3m | 98.8% |
| Growth Correlation 12m | 49.9% |
| Growth Correlation 5y | 50.1% |
| CAGR 5y | 25.82% |
| CAGR/Max DD 3y | 0.53 |
| CAGR/Mean DD 3y | 1.12 |
| Sharpe Ratio 12m | 1.34 |
| Alpha | 0.20 |
| Beta | 0.447 |
| Volatility | 34.86% |
| Current Volume | 1656.8k |
| Average Volume 20d | 1828.3k |
| Stop Loss | 74.3 (-3.1%) |
| Signal | 1.65 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (557.3m TTM) > 0 and > 6% of Revenue (6% = 70.7m TTM) |
| FCFTA 0.26 (>2.0%) and ΔFCFTA 5.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 83.86% (prev 97.84%; Δ -13.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.27 (>3.0%) and CFO 547.8m <= Net Income 557.3m (YES >=105%, WARN >=100%) |
| Net Debt (1.45b) to EBITDA (791.8m) ratio: 1.83 <= 3.0 (WARN <= 3.5) |
| Current Ratio 8.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (124.2m) change vs 12m ago -3.92% (target <= -2.0% for YES) |
| Gross Margin 84.20% (prev 75.89%; Δ 8.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 58.59% (prev 44.34%; Δ 14.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 39.49 (EBITDA TTM 791.8m / Interest Expense TTM 18.0m) >= 6 (WARN >= 3) |
Altman Z'' 6.31
| (A) 0.48 = (Total Current Assets 1.12b - Total Current Liabilities 134.3m) / Total Assets 2.05b |
| (B) 0.18 = Retained Earnings (Balance) 361.0m / Total Assets 2.05b |
| (C) 0.35 = EBIT TTM 710.1m / Avg Total Assets 2.01b |
| (D) 0.19 = Book Value of Equity 332.7m / Total Liabilities 1.72b |
| Total Rating: 6.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.20
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 5.32% = 2.66 |
| 3. FCF Margin 45.87% = 7.50 |
| 4. Debt/Equity 4.94 = -2.50 |
| 5. Debt/Ebitda 2.08 = -0.15 |
| 6. ROIC - WACC (= 23.05)% = 12.50 |
| 7. RoE 136.6% = 2.50 |
| 8. Rev. Trend 84.12% = 6.31 |
| 9. EPS Trend 87.52% = 4.38 |
What is the price of HALO shares?
Over the past week, the price has changed by -1.10%, over one month by +11.19%, over three months by +44.27% and over the past year by +23.06%.
Is Halozyme Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HALO is around 78.86 USD . This means that HALO is currently overvalued and has a potential downside of 2.84%.
Is HALO a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HALO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 70.6 | -8% |
| Analysts Target Price | 70.6 | -8% |
| ValueRay Target Price | 86.4 | 12.6% |
Last update: 2025-09-13 05:02
HALO Fundamental Data Overview
CCE Cash And Equivalents = 548.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 17.7414
P/E Forward = 9.434
P/S = 7.6937
P/B = 27.253
P/EG = -2.5
Beta = 1.195
Revenue TTM = 1.18b USD
EBIT TTM = 710.1m USD
EBITDA TTM = 791.8m USD
Long Term Debt = 1.51b USD (from longTermDebt, last quarter)
Short Term Debt = 134.3m USD (from totalCurrentLiabilities, last quarter)
Debt = 1.64b USD (Calculated: Short Term 134.3m + Long Term 1.51b)
Net Debt = 1.45b USD (from netDebt column, last quarter)
Enterprise Value = 10.16b USD (9.07b + Debt 1.64b - CCE 548.2m)
Interest Coverage Ratio = 39.49 (Ebit TTM 710.1m / Interest Expense TTM 18.0m)
FCF Yield = 5.32% (FCF TTM 540.7m / Enterprise Value 10.16b)
FCF Margin = 45.87% (FCF TTM 540.7m / Revenue TTM 1.18b)
Net Margin = 47.28% (Net Income TTM 557.3m / Revenue TTM 1.18b)
Gross Margin = 84.20% ((Revenue TTM 1.18b - Cost of Revenue TTM 186.2m) / Revenue TTM)
Tobins Q-Ratio = 30.54 (Enterprise Value 10.16b / Book Value Of Equity 332.7m)
Interest Expense / Debt = 0.27% (Interest Expense 4.39m / Debt 1.64b)
Taxrate = 20.29% (113.0m / 557.1m)
NOPAT = 566.0m (EBIT 710.1m * (1 - 20.29%))
Current Ratio = 8.36 (Total Current Assets 1.12b / Total Current Liabilities 134.3m)
Debt / Equity = 4.94 (Debt 1.64b / last Quarter total Stockholder Equity 332.7m)
Debt / EBITDA = 2.08 (Net Debt 1.45b / EBITDA 791.8m)
Debt / FCF = 3.04 (Debt 1.64b / FCF TTM 540.7m)
Total Stockholder Equity = 407.9m (last 4 quarters mean)
RoA = 27.13% (Net Income 557.3m, Total Assets 2.05b )
RoE = 136.6% (Net Income TTM 557.3m / Total Stockholder Equity 407.9m)
RoCE = 37.04% (Ebit 710.1m / (Equity 407.9m + L.T.Debt 1.51b))
RoIC = 29.57% (NOPAT 566.0m / Invested Capital 1.91b)
WACC = 6.52% (E(9.07b)/V(10.71b) * Re(7.66%)) + (D(1.64b)/V(10.71b) * Rd(0.27%) * (1-Tc(0.20)))
Shares Correlation 3-Years: -81.82 | Cagr: -1.05%
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.04% ; FCFE base≈487.7m ; Y1≈584.9m ; Y5≈934.8m
Fair Price DCF = 136.6 (DCF Value 15.98b / Shares Outstanding 117.0m; 5y FCF grow 21.26% → 3.0% )
EPS Correlation: 87.52 | EPS CAGR: 23.76% | SUE: 3.33 | # QB: 6
Revenue Correlation: 84.12 | Revenue CAGR: 17.51% | SUE: 2.19 | # QB: 2
Additional Sources for HALO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle